title: Activity regulates the expression of AMPA receptor subunit GluR4 in developing visual cortex.
abstract: In the developing visual cortex, the expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) subunit GluR4 precedes that of the other AMPAR subunits GluR1-3, and then declines to become almost absent in adults. The current study shows that the neuronal activity regulates the expression of GluR4 by a culture system in vitro and a dark-rearing (DR) system in vivo. Membrane depolarization by treatment of cultured neurons of the visual cortex with a high concentration of KCl (35 mm; HK) promoted a decline in the expression of GluR4. This effect of HK on the expression of GluR4 was significantly blocked by the addition of an N-methyl-d-aspartate receptor (NMDAR) antagonist, (D)-2-amino-5-phosphonovaleric acid (APV), but not by the voltage-sensitive calcium channel antagonist nifedipine. Moreover, the Ca(2+)-calmodulin-dependent kinase (CaMKII) inhibitor KN62 and the cAMP-dependent protein kinase A (PKA) inhibitor H-89 blocked this effect, which suggests the involvement of Ca(2+) influx via NMDAR and the subsequent activation of CaMKII and PKA. Conversely, the MAP kinase inhibitor PD98059 promoted the effect of HK on the expression of GluR4. Significantly, APV, KN62, H-89 and PD98059 either promoted or inhibited the expression of GluR4 even in normal KCl (5 mm) conditions. The developmental change in the expression of GluR4 was significantly attenuated in DR in vivo, and the results suggest that neuronal activity such as visual experience may be involved in the mechanism of the expression of GluR4, which is mediated by NMDAR and tuned by certain protein kinases at an early developmental stage in the visual cortex.
authors: Division of Neurophysiology, Department of Neuroscience, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Japan. akaneya@nphys.med.osaka-u.ac.jp
authors: Yukio
authors: Y
authors: Akaneya
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004622:Embryo, Mammalian; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009543:Nifedipine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D018091:Receptors, AMPA / Q000235:genetics / Q000378:metabolism*; D014793:Visual Cortex / Q000166:cytology* / Q000254:growth & development*
chemical_list: D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA; C104724:glutamate receptor ionotropic, AMPA 4; D011189:Potassium Chloride; D015763:2-Amino-5-phosphonovalerate; D009543:Nifedipine; D002118:Calcium